Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...2627282930313233343536...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Hand-foot syndrome induced by Pembrolizumab for non-small cell lung cancer (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2365;    
    HFS has been described in the literature as an uncommon side effect of many anti-tumor drugs including pembrolizumab but always in combination with other drugs such as capecitabine, lenvatinib and anlotinib. There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer.
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Enrollment change, Combination therapy:  EMERALD-3: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (clinicaltrials.gov) -  Aug 29, 2023   
    P3,  N=725, Recruiting, 
    There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer. N=525 --> 725
  • ||||||||||  Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Neoantigen Derived DCs as Cancer Treatment (clinicaltrials.gov) -  Aug 25, 2023   
    P1,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer. (Pubmed Central) -  Aug 24, 2023   
    Two patients, who showed a reduction with lenvatinib, underwent conversion surgery, which prolonged the prognosis in terms of avoiding events, such as asphyxia, fistula and hemorrhage due to tumor growth; however, the surgical margins were positive, indicating that complete remission was impossible even if surgical resection was performed. Therefore, starting with lenvatinib treatment and identifying a therapeutic drug based on genomic analysis is an acceptable treatment strategy for ATC while halting the disease progression.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Aug 24, 2023   
    P1,  N=11, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Beneficial Role of Multi-Disciplinary Treatment for Anaplastic Thyroid Cancer with Initial Distant Metastasis (Hall B2; In Person Only) -  Aug 22, 2023 - Abstract #ASTRO2023ASTRO_2169;    
    Local treatment combined with chemotherapy for M1 ATC patients showed outcome comparable to those of non-metastatic ATC results. Active local treatment should be considered especially for patients with less than 10 metastases, and patients without distant progression in early response evaluation.
  • ||||||||||  Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases (Hall B2; In Person Only; Screen: 11) -  Aug 22, 2023 - Abstract #ASTRO2023ASTRO_663;    
    Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
  • ||||||||||  E7386 / Eisai, PRISM Pharma
    Trial completion date, Trial primary completion date:  E7386-J081-102: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (clinicaltrials.gov) -  Aug 22, 2023   
    P1b,  N=181, Recruiting, 
    We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis. Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024
  • ||||||||||  zabinostat (CXD101) / IngenOx Therap, Nuance Biotech
    Enrollment open, Checkpoint inhibition:  CXD101 in Immunotherapy-related Liver Cancer (clinicaltrials.gov) -  Aug 22, 2023   
    P2,  N=44, Recruiting, 
    Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma. (Pubmed Central) -  Aug 21, 2023   
    In the current study, we found that the homologous circular RNA (circRNA) of the family with sequence similarity 134, member B (FAM134B), hsa_circ_0128505 (was abbreviated as circFAM134B in the present study), was identified to specifically target ER-phagy to promote lenvatinib (LV)-induced ferroptosis using reactive oxygen species (ROS), Fe, malondialdehyde (MDA), and western blot (WB) assays in HCC cells...circFAM134B was confirmed as a sponge that competitively interacted with PABPC4, thereby influencing FAM134B mRNA nonsense decay. Our results provide novel evidences and strategies for the comprehensive treatment of HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Journal, Metastases:  Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study. (Pubmed Central) -  Aug 21, 2023   
    Furthermore, radiomic features were associated with overall survival and progression-free survival both in the training and validation cohorts, but modified albumin-bilirubin grade and neutrophil-to-lymphocyte ratio were not. Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  Lenvatinib for Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov) -  Aug 21, 2023   
    P2,  N=60, Recruiting, 
    Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen. Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers (clinicaltrials.gov) -  Aug 18, 2023   
    P2,  N=64, Recruiting, 
    Assessing body composition with BIA before Atezo + Beva and Len treatment may be useful. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P2 trial, Metastases:  Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC (clinicaltrials.gov) -  Aug 15, 2023   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Sophoridine derivative 6j inhibits liver cancer cell proliferation via ATF3 mediated ferroptosis. (Pubmed Central) -  Aug 14, 2023   
    Further study revealed that compound 6j upregulated the expression of ATF3 via ER stress and knockdown of ATF3 by RNA interference attenuated 6j induced ferroptosis and cell proliferation inhibition. This study would provide new insights for the design of ferroptosis inducers and the development of anti-liver cancer drugs.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) -  Aug 14, 2023   
    P2,  N=35, Recruiting, 
    These results imply that the dosage of lenvatinib for pediatric patients may need to be augmented in order to attain the desired clinical outcome. Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P3 trial, Metastases:  Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC (clinicaltrials.gov) -  Aug 14, 2023   
    P3,  N=258, Recruiting, 
  • ||||||||||  Clinical guideline, Journal:  SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). (Pubmed Central) -  Aug 9, 2023   
    In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib...When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (clinicaltrials.gov) -  Aug 9, 2023   
    P2,  N=64, Active, not recruiting, 
    While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2022 --> Aug 2022